论文部分内容阅读
目的分析宫颈细胞学阴性且高危型人乳头瘤病毒(HPV)阳性患者的宫颈活检病理结果,探讨Cervista HPV HR A9组病毒应用于此类人群分流的可行性。方法对1 376例于2011年1月至2016年1月健康查体的女性行新柏氏液基细胞学检测(TCT)和Cervista HPV HR检测,Cervista HPV HR检测结果分为A5/6、A7、A9组,将TCT阴性、HPV阳性患者转诊阴道镜检查,必要时行镜下宫颈活检术,分析A9组病毒感染与宫颈高级别上皮内瘤变CINII+(CINII及CINIII)的关系。结果 A5/6组、A7组及A9组阳性者分别占28.41%、21.51%、50.07%。A5/A6组、A7组及A9组中CINII+的发生率分别为1.28%、3.38%、15.82%,A9组中CINII+的发生率明显高于另外两组,其差异具有统计学意义(P<0.001,P<0.001)。A9组病毒感染者发生CINII+的风险是A5/A6组感染者的12.37倍,是A7组感染者的4.68倍。结论 Cervista HPV HR A9组病毒可用于TCT阴性、高危型HPV阳性者的分流。
Objective To analyze the results of cervical biopsy in cervical cytology-negative and high-risk human papillomavirus (HPV) -positive patients and to explore the feasibility of Cervista HPV HR A9 virus in shunting in such population. Methods Totally 1376 women with healthy physical examination from January 2011 to January 2016 were tested with neoboger test and Cervista HPV HR test. The results of Cervista HPV HR test were divided into A5 / 6, A7, In group A9, TCT-negative and HPV-positive patients were referred for colposcopy and if necessary, microscopic cervical biopsy was performed to analyze the relationship between viral infection in group A9 and CINII + (CINII and CINIII) in high-grade cervical intraepithelial neoplasia. Results The positive rates of A5 / 6, A7 and A9 were 28.41%, 21.51% and 50.07% respectively. The incidence of CINII + in group A9, group A7 and group A9 were 1.28%, 3.38% and 15.82%, respectively. The incidence of CINII + in group A9 was significantly higher than that in group A9 (P <0.001) , P <0.001). The risk of CINII + in patients with A9 virus infection was 12.37 times higher than that in A5 / A6 patients and 4.68 times higher than those in A7 patients. Conclusion The Cervista HPV HR A9 virus can be used for shunting TCT-negative and high-risk HPV-positive patients.